FDA Stand On Drug-Combo Exclusivity Was Valid, Judge Says
A now-defunct U.S. Food and Drug Administration policy limiting exclusivity for drugs that combine original and previously approved active ingredients was reasonable, but a revised policy may have to be applied...To view the full article, register now.
Already a subscriber? Click here to view full article